Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Diabetic macular edema (DME) is a sign of diabetic retinopathy that affects central vision.
It is also a leading cause of visual decline in younger patients, especially in developing
countries like our Arab community. Intra-vitrreal injection of anti-vascular endothelial
growth factor (AVEGF) in management of DME had significant improvement in the final logMAR
Un-corrected Distant Visual Acuity ( UCDVA) and logMAR Best Corrected Distant Visual Acuity
(BCDVA), as well as reduction in the central retinal thickness from baseline measurement.